Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity: 2016-2025

Historic Liabilities and Shareholders Equity for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $1.6 billion.

  • Collegium Pharmaceutical's Liabilities and Shareholders Equity fell 1.70% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 31.31%. This contributed to the annual value of $1.7 billion for FY2024, which is 45.51% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Liabilities and Shareholders Equity of $1.6 billion as of Q3 2025, which was up 0.92% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Liabilities and Shareholders Equity registered a high of $1.7 billion during Q4 2024, and its lowest value of $646.1 million during Q1 2021.
  • For the 3-year period, Collegium Pharmaceutical's Liabilities and Shareholders Equity averaged around $1.4 billion, with its median value being $1.2 billion (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 92.88% in 2022, then declined by 13.22% in 2024.
  • Collegium Pharmaceutical's Liabilities and Shareholders Equity (Quarterly) stood at $692.1 million in 2021, then skyrocketed by 69.65% to $1.2 billion in 2022, then decreased by 2.63% to $1.1 billion in 2023, then skyrocketed by 45.51% to $1.7 billion in 2024, then dropped by 1.70% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.6 billion during Q1 2025.